A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION

被引：0
|
作者：
Muir, Andrew [1 ]
Shiffman, Mitchell L. [2 ]
Zaman, Atif [3 ]
Yoffe, Boris [4 ]
Lopez-Talavera, Juan Carlos [5 ]
Souza, Sherri [6 ]
Hausman, Diana F. [6 ]
Lawitz, Eric [7 ]
机构：
[1] Duke Univ, Durham, NC USA
[2] VCU Med Ctr, Richmond, VA USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Bristol Myers Squibb Co, New York, NY 10154 USA
[6] ZymoGenetics Inc, Seattle, WA USA
[7] Alamo Med Res, San Antonio, TX USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1591
引用
收藏
页码：1039A / 1040A
页数：2
相关论文
共 50 条
  • [41] RESPECTIVE QUANTIFICATION OF HEPATITIS C VIRUS GENOTYPE 1B CODON 70 WILD AND MUTANT TYPES AND THEIR RESPONSE TO PEG-IFN/RBV TREATMENT
    Hu, Zhongjie
    Muroyama, Ryosuke
    Goto, Tadashi
    Kowatari, Norie
    Chang, Jin-Hai
    Omata, Masao
    Kato, Naoya
    HEPATOLOGY, 2009, 50 (04) : 712A - 712A
  • [42] Depression and quality of life assessments in HCV genotype-1 patients treated with either consensus interferon (CIFN) and ribavirin (RBV) or pegylated interferon alfa-2b (PEG IFN) and ribavirin
    Bassett, John
    Arias, Manuel
    Maydonovitch, Corinne
    Sjogren, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S131 - S132
  • [43] GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study
    Rodriguez-Torres, M.
    Glass, S.
    Hill, J.
    Freilich, B.
    Hassman, D.
    Di Bisceglie, A. M.
    Taylor, J. G.
    Kirby, B. J.
    Dvory-Sobol, H.
    Yang, J. C.
    An, D.
    Stamm, L. M.
    Brainard, D. M.
    Kim, S.
    Krefetz, D.
    Smith, W.
    Marbury, T.
    Lawitz, E.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (08) : 614 - 622
  • [44] Interferon-α (IFNα) daily dose versus IFNα plus ribavirin for treatment-naive chronic hepatitis C patients infected by genotype 1b
    Scotto, G
    Campanozzi, F
    D'Adduzio, A
    Grimaldi, M
    Fazio, V
    BIODRUGS, 2003, 17 (04) : 281 - 286
  • [45] Interferon-α (IFNα) Daily Dose Versus IFNα Plus Ribavirin for Treatment-Naive Chronic Hepatitis C Patients Infected by Genotype 1b
    Gaetano Scotto
    Fausto Campanozzi
    Antonio D’Adduzio
    Maria Grimaldi
    Vincenzina Fazio
    BioDrugs, 2003, 17 : 281 - 286
  • [46] A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load
    Izumi, N
    Asahina, Y
    Kurosaki, M
    Uchihara, M
    Nishimura, Y
    Inoue, K
    Ueda, K
    Tsuchiya, K
    Hamano, K
    Itakura, J
    Miyake, S
    INTERVIROLOGY, 2004, 47 (02) : 102 - 107
  • [47] Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1
    Nishida, Naoshi
    Iwanishi, Mina
    Minami, Tomohiro
    Chishina, Hirokazu
    Arizumi, Tadaaki
    Takita, Masahiro
    Kitai, Satoshi
    Yada, Norihisa
    Ida, Hiroshi
    Hagiwara, Satoru
    Minami, Yasunori
    Ueshima, Kazuomi
    Sakurai, Toshiharu
    Kitano, Masayuki
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2015, 33 (06) : 708 - 714
  • [48] Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b
    Atsukawa, Masanori
    Tsubota, Akihito
    Kondo, Chisa
    Itokawa, Norio
    Narahara, Yoshiyuki
    Nakatsuka, Katsuhisa
    Hashimoto, Satomi
    Fukuda, Takeshi
    Matsushita, Yoko
    Kidokoro, Hideko
    Kobayashi, Tamaki
    Kanazawa, Hidenori
    Sakamoto, Choitsu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (01) : 51 - 56
  • [49] THE PRESENCE OF HEPATITIS C VIRUS DELETION MUTANTS IN CHRONIC HEPATITIS C PATIENTS AND THEIR ROLE DURING PEG-IFN/RIBAVIRIN THERAPY IN HCV-1 PATIENTS
    Donnici, L.
    Cheroni, C.
    Aghemo, A.
    Rumi, M. G.
    Valveri, V.
    Soffredini, R.
    Prati, G. M.
    Colombo, M.
    Abrignani, S.
    De Francesco, R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S453 - S454
  • [50] Treatment of subjects with chronic hepatitis C infection (HCV) and end stage renal disease (ESRD) using low dose pegylated interferon alpha 2 a (PEG-IFN) and ribavirin (RBV)
    Carriero, Damaris
    Uriel, Alison J.
    Dieterich, Douglas T.
    HEPATOLOGY, 2006, 44 (04) : 337A - 337A
12345